In This Article:
For the quarter ended March 2025, Heron Therapeutics (HRTX) reported revenue of $38.9 million, up 12.2% over the same period last year. EPS came in at $0.01, compared to -$0.02 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $37.08 million, representing a surprise of +4.93%. The company delivered an EPS surprise of +200.00%, with the consensus EPS estimate being -$0.01.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Heron Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
-
Net Product Sales- Oncology- SUSTOL: $2.86 million compared to the $2.98 million average estimate based on two analysts. The reported number represents a change of -20.6% year over year.
-
Net Product Sales- Acute Care- APONVIE: $2.26 million versus $1.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +352% change.
-
Net Product Sales- Acute Care- ZYNRELEF: $8.04 million versus $9.03 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +60.8% change.
-
Net Product Sales- Oncology- CINVANTI: $25.74 million versus $23.10 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +0.6% change.
View all Key Company Metrics for Heron Therapeutics here>>>
Shares of Heron Therapeutics have returned +8.7% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Heron Therapeutics, Inc. (HRTX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).